Chinese Journal of Dermatology ›› 2022, e20210941.doi: 10.35541/cjd.20210941
• Reviews • Previous Articles Next Articles
Tian Cuicui, Chen Hao
Received:
2021-12-29
Revised:
2022-07-13
Online:
2022-01-01
Published:
2022-12-19
Contact:
Chen Hao
E-mail:ch76ch@163. com
Tian Cuicui, Chen Hao. Pathogenesis of cutaneous T-cell lymphoma-related pruritus[J]. Chinese Journal of Dermatology,2022,e20210941. doi:10.35541/cjd.20210941
[1] | Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma[J]. Nat Rev Dis Primers, 2021,7(1):61. doi: 10.1038/ s41572-021-00296-9. |
[2] | Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma[J]. J Pain Symptom Manage, 2013,45(1):114-119. doi: 10.1016/j.jpainsymman.2012.01.012. |
[3] | Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma[J]. Int J Dermatol, 2012,51(8):930-934. doi: 10.1111/j.1365-4632.2011.05188.x. |
[4] | Ottevanger R, Van Beugen S, Evers AWM, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature[J]. J Eur Acad Dermatol Venereol, 2021,35(12):2377-2387. doi: 10.1111/jdv.17570. |
[5] | Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin[J]. J Neurosci, 1997,17(20):8003-8008. doi: 10.1523/jneurosci.17-20-08003.1997. |
[6] | Handwerker HO. Microneurography of pruritus[J]. Neurosci Lett, 2010,470(3):193-196. doi: 10.1016/j.neulet.2009.06.092. |
[7] | Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches[J]. J Allergy Clin Immunol, 2018,142(5):1375-1390. doi: 10.1016/j.jaci.2018.09.005. |
[8] | Wilzopolski J, Kietzmann M, Mishra SK, et al. TRPV1 and TRPA1 channels are both involved downstream of histamine-induced itch[J]. Biomolecules, 2021,11(8):1166. doi: 10.3390/biom11081166. |
[9] | Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch[J]. Nat Neurosci, 2011,14(5):595-602. doi: 10.1038/nn.2789. |
[10] | Wang F, Yang T-L B, Kim BS. The Return of the mast cell: new roles in neuroimmune itch biology[J]. J Invest Dermatol, 2020,140(5):945-951. doi: 10.1016/j.jid.2019.12.011. |
[11] | Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma[J]. Blood, 2012,120(10):2042-2054. doi: 10.1182/blood-2012-03-415638. |
[12] | Shimizu K, Andoh T, Makino T, et al. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression[J]. Eur J Dermatol, 2019,29(3):268-273. doi: 10.1684/ejd.2019.3560. |
[13] | Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia [J]. J Am Acad Dermatol, 2005,52(1):32-39. doi: 10.1016/j.jaad.2004.03.003. |
[14] | Tancrede-Bohin E, Ionescu MA, De La Salmoniere P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas[J]. Arch Dermatol, 2004,140(9):1057-1061. doi: 10.1001/archderm.140.9.1057. |
[15] | Durgin JS, Weiner DM, Wysocka M, et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: pathways and targets for immune restoration and tumor eradication[J]. J Am Acad Dermatol, 2021,84(3):587-595. doi: 10.1016/j.jaad.2020.12.027. |
[16] | Tsianakas A, Stander S. Dupilumab: a milestone in the treatment of atopic dermatitis[J]. Lancet, 2016,387(10013):4-5. doi: 10. 1016/S0140-6736(15)00389-X. |
[17] | Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome[J]. J Eur Acad Dermatol Venereol, 2021,35(6):1331-1337. doi: 10.1111/jdv.17001. |
[18] | Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients[J]. J Am Acad Dermatol, 2020,83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. |
[19] | Hollins LC, Wirth P, Fulchiero GJ, Jr., et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma[J]. Cutis, 2020,106(2):E8-E11. doi: 10.12788/cutis.0074. |
[20] | Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: the "itchy" cytokine in inflammation and therapy[J]. Allergy, 2021,76(10):2982-2997. doi: 10.1111/all.14791. |
[21] | Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin[J]. Acta Derm Venereol, 2016,96(7):894-898. doi: 10.2340/00015555-2417. |
[22] | Abreu M, Miranda M, Castro M, et al. IL-31 and IL-8 in Cutaneous T-Cell lymphoma: looking for their role in itch[J]. Adv Hematol, 2021,2021:5582581. doi: 10.1155/2021/5582581. |
[23] | Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus[J]. J Invest Dermatol, 2013,133(12):2783-2785. doi: 10.1038/jid.2013.227. |
[24] | Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities[J]. Clin Immunol, 2015,158(1):1-7. doi: 10.1016/j.clim.2015.02.014. |
[25] | Skoff A M, Adler J E. Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors[J]. Exp Neurol, 2006,197(2):430-436. doi: 10.1016/j.expneurol. 2005.10.006. |
[26] | Suga H, Sugaya M, Miyagaki T, et al. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma[J]. Acta Derm Venereol, 2013,93(2):144-149. doi: 10.2340/00015555-1428. |
[27] | Azimi E, Reddy VB, Pereira PJS, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch[J]. J Allergy Clin Immunol, 2017,140(2):447-453 e3. doi: 10.1016/j.jaci.2016.12.980. |
[28] | Alam M, Buddenkotte J, Ahmad F, et al. Neurokinin 1 receptor antagonists for pruritus[J]. Drugs, 2021,81(6):621-634. doi: 10.1007/s40265-021-01478-1. |
[29] | Maronas-Jimenez L, Estrach T, Gallardo F, et al. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas[J]. Br J Dermatol, 2018,178(4):e273-e4. doi: 10.1111/bjd.16128. |
[30] | Zic J A, Straka B T, Mcgirt L Y, et al. Aprepitant for the treatment of pruritus in Sezary syndrome: a randomized crossover clinical trial[J]. JAMA Dermatol, 2018,154(10):1221-1222. doi: 10.1001/jamadermatol.2018.2510. |
[31] | Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin[J]. J Neurosci, 2003,23(15):6176-6180. doi: 10.1523/jneurosci.23-15-06176.2003. |
[32] | Sakamoto M, Miyagaki T, Kamijo H, et al. Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome[J]. J Dermatol, 2018,45(1):95-99. doi: 10.1111/1346-8138.14033. |
[33] | Chen Z-F. A neuropeptide code for itch[J]. Nat Rev Neurosci, 2021,22(12):758-776. doi: 10.1038/s41583-021-00526-9. |
[34] | Corder G, Castro DC, Bruchas MR, et al. Endogenous and exogenous opioids in pain[J]. Annu Rev Neurosci, 2018,41:453-473. doi: 10.1146/annurev-neuro-080317-061522. |
[35] | Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review[J]. J Am Acad Dermatol, 2010,63(4):680-688. doi: 10.1016/j.jaad.2009. 08.052. |
[36] | Wang Z, Jiang C, Yao H, et al. Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition[J]. Brain, 2021,144(2):665-681. doi: 10.1093/brain/awaa430. |
[1] | Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664. |
[2] | Jiang Xian, Liu Lian, Zhang Ting. Treatment of port-wine stains: current status and prospects [J]. Chinese Journal of Dermatology, 2024, 57(7): 590-594. |
[3] | Feng Mengdi, Wang Wenqing. Regulatory roles of transcription factors and receptors in the pathogenesis of acne [J]. Chinese Journal of Dermatology, 2024, 57(6): 575-578. |
[4] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[5] | China Dermatologist Association. Guidelines for the management of chronic pruritus (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399. |
[6] | Ju Qiang, Li Jiaqi. Acne vulgaris revisited: from pathogenesis to treatment strategies [J]. Chinese Journal of Dermatology, 2024, 57(4): 289-294. |
[7] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[8] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
[9] | Zheng Yaxuan, Su Huichun. Role of sweat in the pathogenesis of cholinergic urticaria [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230055-e20230055. |
[10] | Liu Tingwei, Meng Xiaoqi, Gu Duoduo, Pan Ruoxin, Zhang Yue, Xu Yang. Advances in the pathogenesis of rosacea [J]. Chinese Journal of Dermatology, 2024, 57(2): 186-190. |
[11] | Shao Yi, Wang Lei, Liu Fang. A comparative clinicopathologic analysis of mycosis fungoides with large cell transformation versus primary cutaneous anaplastic large cell lymphoma [J]. Chinese Journal of Dermatology, 2023, 56(9): 853-857. |
[12] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
[13] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
[14] | Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus ()”. Treatment of mycosis fungoides: a Chinese expert consensus (2023) [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409. |
[15] | Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210803-e20210803. |
|